CDMO Selection Criteria for EU Peptide API Manufacturing: A Decision Framework
Key evaluation dimensions for selecting a European peptide CDMO: synthesis technology capabilities, quality systems maturity, regulatory track record, and commercial terms.
The EU Peptide CDMO Market: Overview
The European contract development and manufacturing market for synthetic peptides has consolidated significantly since 2018, with a handful of specialised CDMOs capable of multi-gram to kilogram-scale GMP synthesis. Selecting the right partner requires a structured, multi-dimensional evaluation rather than price-only procurement.
Synthesis Technology Assessment
Solid-phase peptide synthesis (SPPS) remains the dominant technology for clinical-stage peptides. Key capability indicators include: resin loading capacity (mol/g), maximum synthesis scale (mmol), available cleavage infrastructure (TFA volumes, HF capability for certain chemistries), and purification throughput via preparative reversed-phase HPLC. For longer or complex sequences, evaluate solution-phase segment condensation capabilities and native chemical ligation expertise.
GMP Quality Systems Maturity
EU GMP compliance, assessed through EMA and national competent authority (NCA) inspection records, is a baseline requirement. Beyond certification, evaluate: QMS documentation completeness, OOS investigation quality, change control rigour, and audit response times. Request recent annual product review (APR) summaries as performance indicators.
Regulatory Filing Support
CDMO regulatory affairs capability is increasingly critical for CTD Module 3.2.S drug substance sections. Evaluate experience with EU Drug Master File (DMF/ASMF) submissions, Type II variation support, and responsiveness to EMA Day 90/120 questions on peptide characterisation.
Commercial and Capacity Considerations
Technology transfer timelines, minimum order quantities, dedicated versus multi-product facility options, and force majeure provisions are commercial terms that significantly affect programme risk profiles. Negotiate supply agreements with clear change notification obligations and business continuity provisions.